PMID- 36082602
OWN - NLM
STAT- MEDLINE
DCOM- 20220912
LR  - 20220912
IS  - 0370-629X (Print)
IS  - 0370-629X (Linking)
VI  - 77
IP  - 9
DP  - 2022 Sep
TI  - [Nasal glucagon (Baqsimi®), new treatment for hypoglycaemic coma].
PG  - 538-543
AB  - Patients with insulin-treated type 1 diabetes (T1D) are exposed to hypoglycaemia, 
      which may be serious. Serious cognitive impairment (including coma and seizure) 
      that requires the help of a third party is a medical emergency. Besides the 
      intravenous injection of glucose by a health care provider, its treatment 
      consists of the subcutaneous or intramuscular injection of glucagon which may be 
      performed by a family member. However, such an injection is not easy and puts off 
      some people, which retards the initiation of a potentially life-saving therapy. 
      The intranasal administration of 3 mg glucagon has been shown as efficacious as 
      the subcutaneous or intramuscular injection of 1 mg glucagon in controlled 
      studies carried out in both adult and youth patients with T1D. Stimulation and 
      real-life studies among caregivers, patients and acquaintances showed a 
      preference for nasal glucagon because of its easy and quick use. The launch of 
      nasal glucagon (Baqsimi®) offers new perspectives for the ambulatory emergency 
      management of severe hypoglycaemia and hypoglycaemic coma with a special obvious 
      advantage in children.
FAU - Philips, J C
AU  - Philips JC
AD  - Service de Diabétologie, Nutrition et Maladies métaboliques, Département de 
      Médecine interne, CHU Liège, Belgique.
FAU - Radermecker, R P
AU  - Radermecker RP
AD  - Service de Diabétologie, Nutrition et Maladies métaboliques, Département de 
      Médecine interne, CHU Liège, Belgique.
FAU - Lebrethon, M C
AU  - Lebrethon MC
AD  - Service de Pédiatrie, CHU NDB, Liège, Belgique.
FAU - S, Scheen
AU  - S S
AD  - Service de Diabétologie, Nutrition et Maladies métaboliques, Département de 
      Médecine interne, CHU Liège, Belgique.
LA  - fre
PT  - Journal Article
TT  - Le médicament du mois. Le glucagon nasal (Baqsimi®), nouveau traitement du coma 
      hypoglycémique.
PL  - Belgium
TA  - Rev Med Liege
JT  - Revue medicale de Liege
JID - 0404317
RN  - 0 (Blood Glucose)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin)
RN  - 9007-92-5 (Glucagon)
SB  - IM
MH  - Adolescent
MH  - Adult
MH  - Blood Glucose
MH  - Child
MH  - Coma/chemically induced
MH  - *Diabetes Mellitus, Type 1/complications/drug therapy
MH  - Glucagon/adverse effects/therapeutic use
MH  - Humans
MH  - *Hypoglycemia/chemically induced
MH  - Hypoglycemic Agents/adverse effects
MH  - Insulin
OTO - NOTNLM
OT  - Coma
OT  - Emergency therapy
OT  - Glucagon
OT  - Hypoglycaemia
OT  - Type 1 diabetes
OT  - Child
EDAT- 2022/09/10 06:00
MHDA- 2022/09/14 06:00
CRDT- 2022/09/09 04:14
PHST- 2022/09/09 04:14 [entrez]
PHST- 2022/09/10 06:00 [pubmed]
PHST- 2022/09/14 06:00 [medline]
PST - ppublish
SO  - Rev Med Liege. 2022 Sep;77(9):538-543.